Stock Updates

Morning Trending Tickers: Vertex Pharmaceuticals Incorporated, (VRTX)

Friday February 24th 2017: Vertex Pharmaceuticals Incorporated, VRTX is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Vertex Pharmaceuticals Incorporated, VRTX  has a market cap of 32.88 B. Since its IPO date on the 7/24/1991, Vertex Pharmaceuticals Incorporated, VRTX performance year to date is 78.42%. Today Vertex Pharmaceuticals Incorporated, VRTX has gained -1.67%, with a current price of 129.25.

Ownership of the company is 0.50% for insider ownership while institutional ownership is 99.90%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 6.40%, with return on investment at -0.30%.

In terms of debt levels and profit levels, Vertex Pharmaceuticals Incorporated, VRTX is seeing a long-term debt/equity of 0.35. While Total debt/equity is 0.37. With a profit margin of 8.80%, this is combined with a gross margin of 89.90%, and operating margin of 14.60%. Vertex Pharmaceuticals Incorporated ability to meet debt levels, with a current ratio of 3.8, while the quick ratio is 3.7.

For the last year Vertex Pharmaceuticals Incorporated, VRTX has seen a EPS growth of 80.10%. A performance for the year of 46.65%. The 52-week high is -5.84%, and the 52-week low is 80.87%. The average volume for Vertex Pharmaceuticals Incorporated, VRTX is 558306.

With a target price of 127.13, can Vertex Pharmaceuticals Incorporated, VRTX reach this target? Looking at the value indicators of Vertex Pharmaceuticals Incorporated, VRTX. Vertex Pharmaceuticals Incorporated has a P/E of 185.65 and a forward P/E of 42.07. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.03. Vertex Pharmaceuticals Incorporated also has a P/S and a P/B of 16.28 and 21.55 respectively. For P/cash, Vertex Pharmaceuticals Incorporated has a value of 23.34, while it is 71.28 for P/free cash flow.

At the current price of 129.25, Vertex Pharmaceuticals Incorporated has a dividend yield of *TBA. We see a return on equity of 15.20%.

Looking more long-term Vertex Pharmaceuticals Incorporated, is projected to get an EPS growth for the next five years of 61.37%. In the short-term an EPS growth of 87.97% in the next year is forecasted. This is after a EPS growth of 80.10% for this year and for the last five years a -39.40% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Mark Hines

Leave a Comment